Viewing nowCombinationHypoGIA Tablet 5/80/10 mg
Amlodipine Besylate 6.94mg · Valsartan 80mg +1 more
Tablet · Prescription medication · Combination
Genewon Sciences Co., Ltd.

MFDS item code 202105297 · Approved 2021.07.12 · Insurance code 671706960
Treatment of hypertension and dyslipidemia; prevention of cardiovascular disease (myocardial infarction, stroke, etc.)
This medication is used in patients with essential hypertension who have difficulty controlling blood pressure with amlodipine and valsartan monotherapy, and in patients with dyslipidemia or those at risk of cardiovascular disease who require atorvastatin. The combination of amlodipine and valsartan effectively lowers blood pressure, helping to control hypertension, while atorvastatin improves serum cholesterol and triglyceride levels, reducing the risk of cardiovascular events such as myocardial infarction and stroke. Additionally, atorvastatin aids in reducing cardiovascular risks in diabetic patients with coronary heart disease risk factors. By administering these two medications together, both blood pressure and blood lipids can be managed simultaneously, effectively improving cardiovascular health. Therefore, this medication is used in the treatment of patients with both hypertension and dyslipidemia.
Take 1 tablet once daily with water. It is recommended to take this medicine at the same time each day, if possible (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/valsartan combination and atorvastatin. Patients taking an amlodipine/valsartan combination and atorvastatin as separate medicines may switch to this medicine (a combination tablet containing the same amounts of each active ingredient) for convenience. ▷ Amlodipine/valsartan combination Before administering the amlodipine/valsartan combination, it is recommended that the dose of each individual component (amlodipine or valsartan) be adjusted. However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to the amlodipine/valsartan combination may be considered as follows. ㆍ5/80 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy. ㆍ5/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg monotherapy. ㆍ10/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg monotherapy, or with 5/160 mg. - Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or higher). However, the amlodipine/valsartan combination should not be administered to patients with severe renal impairment (creatinine clearance below 10mL/min) or patients on dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. - Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. Do not administer the amlodipine/valsartan combination to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. - Elderly patients aged 65 years or older: Use caution when increasing the dose. ▷ Atorvastatin Patients receiving atorvastatin, both before and during treatment, should follow a standard cholesterol-lowering diet. The medicine may be taken at any time of day, with or without food. 1. Dyslipidemia The recommended initial dose is 10 mg of atorvastatin once daily. For patients requiring a greater reduction in LDL cholesterol, treatment may be initiated at 20 mg or 40 mg once daily (only when a reduction in LDL cholesterol of 45 % or more is required). This medicine is administered once daily in a dose range of 10 ~ 80 mg. The initial and maintenance doses should be individualized according to the patient's characteristics, taking into account the treatment goal and response. Lipid levels should be analyzed within 2 ~ 4 weeks after starting treatment and/or dose titration, and the dose should be adjusted accordingly. Because the treatment goal is to lower LDL cholesterol, LDL cholesterol is recommended for use at the start of treatment and when evaluating response. However, if LDL cholesterol levels are unavailable, total cholesterol should be used to monitor response to treatment. Patients with homozygous familial hypercholesterolemia The dose is 10 ~ 80 mg once daily. Administer this medicine in combination with other lipid-lowering treatments (e.g., LDL apheresis), or when such treatments are not available. - Patients with renal impairment: Renal disease does not affect plasma concentrations of atorvastatin or its LDL cholesterol-lowering effect; therefore, no dosage adjustment is necessary. - Elderly patients: Efficacy and safety in patients aged 70 years or older are generally similar to those in the general adult patient population.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. If there is a significant increase in muscle-related disorders or muscle pain, or if creatine kinase levels rise significantly, use should be discontinued due to the risk of serious muscle damage leading to kidney failure. This medication should not be used in patients with specific liver disorders, severe kidney disorders, pregnant or potentially pregnant women, or patients with hypersensitivity. Patients with insufficient body sodium or fluids, those with hyperkalemia, and patients with kidney or heart problems should be closely monitored while taking this medication. Caution is needed as dizziness or fatigue may occur while driving or operating machinery. Regular checks of liver and kidney function should be conducted during use, and if severe muscle pain or weakness occurs, immediate consultation with a physician is required. Interactions may occur when taken with other medications, so all medications being taken should be disclosed to a physician or pharmacist. Pregnant or breastfeeding women should not take this medication, and fertile women should use appropriate contraception. It is recommended that this medication not be used in children.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. The appropriate storage temperature is room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the efficacy of the medication for a long time.
White oval film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 6.94mg · Valsartan 80mg +1 more
Tablet · Prescription medication · Combination
Genewon Sciences Co., Ltd.
Amlodipine Besylate 6.94mg · Valsartan 80mg +1 more
Tablet · Prescription medication · Combination
HK Inno.N Co., Ltd.
Amlodipine Besylate 6.94mg · Valsartan 80mg +1 more
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
Amlodipine Besylate 6.94mg · Valsartan 160mg +1 more
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
Amlodipine Besylate 6.94mg · Valsartan 160mg +1 more
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
CombinationAmlodipine Besylate 6.94mg · Valsartan 80mg +1 more
Tablet · Prescription medication · Combination
Dongu Bio Pharmaceutical Co., Ltd.
CombinationAmlodipine Besylate 6.94mg · Valsartan 80mg +1 more
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationAmlodipine Besylate 6.94mg · Valsartan 160mg +1 more
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.